• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种将发病率与死亡率相结合的癌症负担单一指标,供全球使用。

A single measure of cancer burden combining incidence with mortality rates for worldwide application.

作者信息

Kim Jeong Lim, Cho Kyoung-Hee, Park Eun-Cheol, Cho Woo Hyun

机构信息

Department of Public Health, Graduate School, Yonsei University, Seould, Korea E-mail :

出版信息

Asian Pac J Cancer Prev. 2014;15(1):433-9. doi: 10.7314/apjcp.2014.15.1.433.

DOI:10.7314/apjcp.2014.15.1.433
PMID:24528070
Abstract

We attempted to develop an indicator combining incidence and mortality (summary indicator of cancer burden, SMCB) and to compare the magnitudes of cancer burden by world region. The SMCB was used to measure the size of cancer burden summarizing the incidence and mortality. The incidence and mortality were divided in equivalent forms and were split. The criteria dividing the size of cancer burden were used as the maximum incidence and mortality by men and women according to the world database, and the value corresponding to 10% of each maximum was set as the cut-off value. In SMCB, the size of cancer burden was highest for men with lung cancer (SMCB=18) and for women with breast cancer (SMCB=14) in MDR (more developed regions) compared to the size of burden in LDR (lower developed regions) (lung, SMCB=11, breast, SMCB=8). For men, the size of cancer burden by region was highest in EURO (SMCB=18, lung), followed by WPRO (SMCB=16, lung), PAHO (SMCB=14, prostate), AFRO (SMCB=8, prostate) and SEARO (SMCB=7, lung). Moreover, for women, the size of cancer burden was greatest in EURO (SMCB=14, breast), followed by PAHO (SMCB=13, breast), AFRO (SMCB=11, cervix uteri), EMRO (SMCB=9, breast) or SEARO (SMCB=8, cervix uteri) and WPRO (SMCB=7, lung). The summary indicator will help to provide a priority setting for reducing cancer burden in health policy.

摘要

我们试图开发一种结合发病率和死亡率的指标(癌症负担汇总指标,SMCB),并比较世界各地区癌症负担的大小。SMCB用于衡量汇总发病率和死亡率的癌症负担规模。发病率和死亡率以等效形式划分并进行了拆分。划分癌症负担规模的标准依据世界数据库中男性和女性的最高发病率和死亡率确定,每个最高值的10%对应的数值被设定为临界值。在SMCB中,与低发展中地区(LDR)的负担规模相比,在高发展中地区(MDR),男性肺癌的癌症负担规模最高(SMCB = 18),女性乳腺癌的癌症负担规模最高(SMCB = 14)(肺癌,LDR的SMCB = 11,乳腺癌,LDR的SMCB = 8)。对于男性,按地区划分的癌症负担规模在欧洲区域(EURO,SMCB = 18,肺癌)最高,其次是西太平洋区域(WPRO,SMCB = 16,肺癌)、泛美卫生组织区域(PAHO,SMCB = 14,前列腺癌)、非洲区域(AFRO,SMCB = 8,前列腺癌)和东南亚区域(SEARO,SMCB = 7,肺癌)。此外,对于女性,癌症负担规模在欧洲区域最大(EURO,SMCB = 14,乳腺癌),其次是泛美卫生组织区域(PAHO,SMCB = 13,乳腺癌)、非洲区域(AFRO,SMCB = 11,子宫颈癌)、东地中海区域(EMRO,SMCB = 9,乳腺癌)或东南亚区域(SEARO,SMCB = 8,子宫颈癌)以及西太平洋区域(WPRO,SMCB = 7,肺癌)。该汇总指标将有助于在卫生政策中为减轻癌症负担确定优先事项。

相似文献

1
A single measure of cancer burden combining incidence with mortality rates for worldwide application.一种将发病率与死亡率相结合的癌症负担单一指标,供全球使用。
Asian Pac J Cancer Prev. 2014;15(1):433-9. doi: 10.7314/apjcp.2014.15.1.433.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
A single measure of cancer burden in Korea from 1999 to 2010.
Asian Pac J Cancer Prev. 2013;14(9):5249-55. doi: 10.7314/apjcp.2013.14.9.5249.
4
Global patterns and trends in colorectal cancer incidence and mortality.全球结直肠癌发病率和死亡率的模式和趋势。
Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27.
5
Cancer in developing countries.发展中国家的癌症
Cancer Surv. 1994;19-20:519-61.
6
Global Trend of Breast Cancer Mortality Rate: A 25-Year Study.全球乳腺癌死亡率趋势:一项为期25年的研究。
Asian Pac J Cancer Prev. 2019 Jul 1;20(7):2015-2020. doi: 10.31557/APJCP.2019.20.7.2015.
7
Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000.按部位划分的全球及区域癌症死亡率和发病率估计:II. 2000年全球疾病负担结果
BMC Cancer. 2002 Dec 26;2:37. doi: 10.1186/1471-2407-2-37.
8
International variations and trends in testicular cancer incidence and mortality.国际睾丸癌发病率和死亡率的变化和趋势。
Eur Urol. 2014 Jun;65(6):1095-106. doi: 10.1016/j.eururo.2013.11.004. Epub 2013 Nov 14.
9
International variations in bladder cancer incidence and mortality.膀胱癌发病率和死亡率的国际差异。
Eur Urol. 2014 Jul;66(1):59-73. doi: 10.1016/j.eururo.2013.10.001. Epub 2013 Oct 16.
10
Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries.全球前列腺癌发病率和死亡率:36 个国家时间模式和趋势分析。
Eur Urol. 2016 Nov;70(5):862-874. doi: 10.1016/j.eururo.2016.05.043. Epub 2016 Jun 8.

引用本文的文献

1
Comparative Evaluation of Captopril, Spironolactone, and Carvedilol Effect on Endothelial Function in Breast Cancer Women Undergoing Chemotherapy.卡托普利、螺内酯和卡维地洛对接受化疗的乳腺癌女性内皮功能影响的比较评估
Adv Biomed Res. 2023 May 15;12:116. doi: 10.4103/abr.abr_81_21. eCollection 2023.
2
Pan-cancer analysis reveals the role of long non-coding RNA LINC01614 as a highly cancer-dependent oncogene and biomarker.泛癌分析揭示了长链非编码RNA LINC01614作为一种高度依赖癌症的致癌基因和生物标志物的作用。
Oncol Lett. 2020 Aug;20(2):1383-1399. doi: 10.3892/ol.2020.11648. Epub 2020 May 20.
3
Prognostic value of long non-coding RNA GHET1 in cancers: a systematic review and meta-analysis.
长链非编码RNA GHET1在癌症中的预后价值:一项系统评价和荟萃分析。
Cancer Cell Int. 2020 Apr 7;20:109. doi: 10.1186/s12935-020-01189-9. eCollection 2020.
4
Survival Rate of Breast Cancer in Eastern Mediterranean Region Countries: A Systematic Review and Meta-Analysis.《东地中海区域国家乳腺癌生存率:系统评价和荟萃分析》。
Ann Glob Health. 2019 Dec 4;85(1):138. doi: 10.5334/aogh.2521.
5
Ranking composite Cancer Burden Indices for geographic regions: point and interval estimates.地理区域综合癌症负担指数排名:点估计和区间估计
Cancer Causes Control. 2018 Feb;29(2):279-287. doi: 10.1007/s10552-018-1000-9. Epub 2018 Jan 25.
6
Meyer prevents radiation-induced liver injury via modulation of oxidative stress and apoptosis.迈耶通过调节氧化应激和细胞凋亡来预防辐射诱导的肝损伤。
J Ginseng Res. 2017 Apr;41(2):159-168. doi: 10.1016/j.jgr.2016.02.006. Epub 2016 Mar 3.
7
G-Protein Signaling Protein-17 (RGS17) Is Upregulated and Promotes Tumor Growth and Migration in Human Colorectal Carcinoma.G 蛋白信号转导蛋白 17(RGS17)在人结直肠癌中上调并促进肿瘤生长和迁移。
Oncol Res. 2018 Jan 19;26(1):27-35. doi: 10.3727/096504017X14900515946914. Epub 2017 Mar 23.
8
WNT2 Promotes Cervical Carcinoma Metastasis and Induction of Epithelial-Mesenchymal Transition.WNT2促进宫颈癌转移并诱导上皮-间质转化。
PLoS One. 2016 Aug 11;11(8):e0160414. doi: 10.1371/journal.pone.0160414. eCollection 2016.
9
Down-regulated microRNA-124 expression as predictive biomarker and its prognostic significance with clinicopathological features in breast cancer patients.下调的微小RNA-124表达作为预测性生物标志物及其在乳腺癌患者中与临床病理特征的预后意义。
Diagn Pathol. 2015 Sep 29;10:178. doi: 10.1186/s13000-015-0391-0.
10
Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.前列腺良性和恶性细胞中膳食脂肪酸的差异利用
PLoS One. 2015 Aug 18;10(8):e0135704. doi: 10.1371/journal.pone.0135704. eCollection 2015.